The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Orcoda (ASX:ODA) welcomes Maree Adshead as an independent Non-Executive Director
  • She has more than 30 years of board and advisory experience in Australia
  • Ms Adshead currently serves as Chair at Turbine Sunshine Coast and is the CEO of Eco-Markets Australia
  • Shares in ODA last traded at 25.5 cents

Orcoda (ASX:ODA) has welcomed Maree Adshead as an independent Non-Executive Director.

“Her extensive advisory experience and strong connections within the Australian business community will be invaluable as the Company continues to advance its smart city transport solutions,” ODA Chair Nicholas Johansen said.

With more than 30 years of board and advisory experience in Australia, she currently serves as Chair at Turbine Sunshine Coast and is the CEO of Eco-Markets Australia.

Ms Adshead has held other significant roles in the Queensland public service sector, including Queensland Small Business Commissioner, and was an ex-partner at Minter Ellison Lawyers.

She recently concluded her tenure as a member of the Advisory Council to the Energy and Water Ombudsman Queensland and the Moreton Bay Regional Council’s Economic Development Taskforce.

ODA last traded at 25.5 cents.

ODA by the numbers
More From The Market Online
Image of four gold necklaces

Sales growth pushes Lovisa’s fortunes (and shares) upwards

Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and…
Organised crime concept

Panic, paranoia, and gangland politics: HotCopper users react to Dubber’s missing $26M

HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due…
Market Update Graphic

ASX Market Update: Bourse nears record approaching week’s end | November 22, 2024

The bourse is near record territory to close out the week on the back of a…
Image of eyes in closeup

Scientific conference spotlights PYC’s work on blindness disease treatment

PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat…